Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Blueprint Medicines Corporation is a biotechnology business based in the US. Blueprint Medicines Corporation shares (BPMC) are listed on the NASDAQ and all prices are listed in US Dollars. Blueprint Medicines Corporation employs 476 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $73.15 |
|---|---|
| 52-week range | $74.75 - $117.86 |
| 50-day moving average | $102.61 |
| 200-day moving average | $96.16 |
| Wall St. target price | $120.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-7.12 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $73.15 from 2022-01-18
| 1 week (2022-01-13) | -3.61% |
|---|---|
| 1 month (2021-12-20) | -30.85% |
| 3 months (2021-10-20) | -28.43% |
| 6 months (2021-07-20) | -14.91% |
| 1 year (2021-01-20) | -29.81% |
|---|---|
| 2 years (2020-01-17) | -9.80% |
| 3 years (2019-01-18) | 4.47% |
| 5 years (2017-01-20) | 126.40% |
Valuing Blueprint Medicines Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Blueprint Medicines Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Blueprint Medicines Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $345.2 million.
The EBITDA is a measure of a Blueprint Medicines Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $107.2 million |
|---|---|
| Gross profit TTM | $466.5 million |
| Return on assets TTM | -16.96% |
| Return on equity TTM | -32.03% |
| Profit margin | 0% |
| Book value | $21.20 |
| Market capitalisation | $4.6 billion |
TTM: trailing 12 months
We're not expecting Blueprint Medicines Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Blueprint Medicines Corporation's shares have ranged in value from as little as $74.75 up to $117.86. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Blueprint Medicines Corporation's is 0.7172. This would suggest that Blueprint Medicines Corporation's shares are less volatile than average (for this exchange).
Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc. ; CStone Pharmaceuticals; Genentech, Inc. ; and F.
Donut earns up to 10% APY, but you must have an iOS device.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.